Paper41333157
Integrative Multi-Omics and Functional Characterization Reveal MCM4 as a Key Oncogenic Regulator in Hepatocellular Carcinoma.
Qiu M and 1 other. Onco Targets Ther, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Integrative Multi-Omics and Functional Characterization Reveal MCM4 as a Key Oncogenic Regulator in Hepatocellular Carcinoma. Papers, record 41333157. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41333157
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Integrative Multi-Omics and Functional Characterization Reveal MCM4 as a Key Oncogenic Regulator in Hepatocellular Carcinoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28537669 | E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival. | Eur Rev Med Pharmacol Sci | 2017 | https://conductscience.org/library/papers/28537669 | PubMed |
| 2 | 39911278 | Integrative Bioinformatics Analysis for Targeting Hub Genes in Hepatocellular Carcinoma Treatment. | Curr Genomics | 2025 | https://conductscience.org/library/papers/39911278 | PubMed |
| 3 | 37737200 | MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma. | Diagn Pathol | 2023 | https://conductscience.org/library/papers/37737200 | PubMed |
| 4 | 38499612 | Multi-omics pan-cancer analyses identify MCM4 as a promising prognostic and diagnostic biomarker. | Sci Rep | 2024 | https://conductscience.org/library/papers/38499612 | PubMed |
| 5 | 19920109 | DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19920109 | PubMed |
| 6 | 12714602 | Identification of MCM4 as a target of the DNA replication block checkpoint system. | J Biol Chem | 2003 | https://conductscience.org/library/papers/12714602 | PubMed |
| 7 | 35830849 | Minichromosome Maintenance 4 Is Associated with Cancer Stemness and Poor Survival of Patients with Gastric Cancer. | Pathobiology | 2023 | https://conductscience.org/library/papers/35830849 | PubMed |
| 8 | 39915447 | Hepatocellular carcinoma: signaling pathways and therapeutic advances. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/39915447 | PubMed |
| 9 | 34172788 | MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. | Sci Rep | 2021 | https://conductscience.org/library/papers/34172788 | PubMed |
| 10 | 28125050 | Links between DNA Replication, Stem Cells and Cancer. | Genes (Basel) | 2017 | https://conductscience.org/library/papers/28125050 | PubMed |
| 11 | 35719366 | Comprehensive Analysis of the Expression and Prognosis for MCM4 in Uterine Corpus Endometrial Carcinoma. | Front Genet | 2022 | https://conductscience.org/library/papers/35719366 | PubMed |
| 12 | 37612741 | Advances in single-cell RNA sequencing and its applications in cancer research. | J Hematol Oncol | 2023 | https://conductscience.org/library/papers/37612741 | PubMed |
| 13 | 32822825 | MCM family in gastrointestinal cancer and other malignancies: From functional characterization to clinical implication. | Biochim Biophys Acta Rev Cancer | 2020 | https://conductscience.org/library/papers/32822825 | PubMed |
| 14 | 16133572 | MCM4 expression in esophageal cancer from southern China and its clinical significance. | J Cancer Res Clin Oncol | 2005 | https://conductscience.org/library/papers/16133572 | PubMed |
| 15 | 39709431 | Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. | J Hematol Oncol | 2024 | https://conductscience.org/library/papers/39709431 | PubMed |
| 16 | 39866810 | The Prognostic Significance of TRs in Hepatocellular Carcinoma: Insights from TCGA and GEO Databases. | Biomark Insights | 2025 | https://conductscience.org/library/papers/39866810 | PubMed |
| 17 | 23881943 | The minichromosome maintenance replicative helicase. | Cold Spring Harb Perspect Biol | 2013 | https://conductscience.org/library/papers/23881943 | PubMed |
| 18 | 36303105 | MCM2 in human cancer: functions, mechanisms, and clinical significance. | Mol Med | 2022 | https://conductscience.org/library/papers/36303105 | PubMed |
| 19 | 36882493 | Differentially expressed discriminative genes and significant meta-hub genes based key genes identification for hepatocellular carcinoma using statistical machine learning. | Sci Rep | 2023 | https://conductscience.org/library/papers/36882493 | PubMed |
| 20 | 37198697 | EZH2 regulates pancreatic cancer cells through E2F1, GLI1, CDK3, and Mcm4. | Hereditas | 2023 | https://conductscience.org/library/papers/37198697 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MCM4 | 4173 | PubTator's text mining | https://conductscience.org/library/genes/4173 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41333157
GET https://conductscience.org/api/papers/v1/41333157/references?page=2